Clinical Evaluation of Hepatocarcinogenesis and Outcome Using a Novel Glycobiomarker Wisteria floribunda Agglutinin-Positive Mac-2 Binding Protein (WFA+-M2BP) in Chronic Hepatitis C with Advanced Fibrosis

Japanese journal of infectious diseases

Yuji Tsuzuki¹  Takako Inoue²  Etsuko Iio³  Noboru Shinkai⁴ 

[1] Clinical Laboratory, Nagoya City University Hospital;Department of Clinical Laboratory Medicine, Nagoya City University Hospital;Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences;Department of Virology and Liver Unit, Nagoya City University Graduate School of Medical Sciences

关键词: Wisteria floribunda agglutinin-positive-Mac-2 binding protein (WFA+-M2BP);    chronic hepatitis C (CHC);    glycobiomarker;    liver fibrosis;    hepatocarcinogenesis;   

DOI  :  10.7883/yoken.JJID.2017.459

学科分类：传染病学

来源: National Institute of Infectious Diseases

【 摘 要 】

This study aimed to assess the association between the serum glycobiomarker Wisteria floribunda agglutinin-positive Mac-2 binding protein (WFA+-M2BP) for liver fibrosis and outcomes and carcinogenesis of hepatocellular carcinoma (HCC) in chronic hepatitis C (CHC) patients with advanced fibrosis. Serum WFA+-M2BP levels were measured in 128 consecutive CHC patients including 49 with HCC histopathologically diagnosed with advanced fibrosis (44 with fibrosis stage F3 and 84 with fibrosis stage F4) in our hospital. The median WFA+-M2BP level was significantly higher in F4 than in F3 patients (6.9 vs. 2.3 cutoff index [COI], respectively; p<0.001). The difference in WFA+-M2BP levels between patients with and without HCC was not significant. The respective 5-/8-yr survival rates of patients without HCC at enrollment with high (≥4 COI, n=39), intermediate (1–4 COI, n=33), and low WFA+-M2BP (<1 COI, n=7) levels were 78%/48%, 100%/82%, and 100%/100%, respectively. The differences in survival rates between groups were significant (p=0.0041). Patients with high WFA+-M2BP levels had a significantly higher incidence of HCC than those with low WFA+-M2BP levels (p=0.0019). Cumulative 5-yr carcinogenesis rates in patients with high, intermediate, and low WFA+-M2BP levels were 48.7%, 16.9%, and 0%, respectively; the differences between groups were significant (p=0.002). Serum WFA+-M2BP levels might allow the prediction of carcinogenesis and outcome in CHC patients with advanced fibrosis.

【 授权许可】

Unknown